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The adjuvant treatments dependent on ﬁndings from lumpectomy and SLN specimens. The aim of this study is to determine
the prevalence of addiction disease in patient with micrometastatic sentinel node and assess potential predictors factors.
Materials and methods. Retrospective analysis of 1213 patients in the University Hospital of Vigo and Pontevedra with breast
cancer in stage T1–T2 selecting those with micrometastases in the sentinel lymph node biopsy (SLNB), between January 2007
and December 2011. Excluding subjects with chemotherapy neoadjuvant, surgery and/or radiotherapy and no migration of the
radiotracer.
Results. We revised 1213 SLNB: 254 (20.9%) macrometastases followed by ALND (pN1a1b2), 101 micrometastases (8.32%), 38 (3.1%)
isolated cells (pN0 (i+)), 820 (67.6%) negative (pN0(i−)). Micrometastases (101) in SLNB: 25 (24.7%) patients were not performed
ALND, of these 13 received radiotherapy axillaries chains. All without relapse of disease and free of side effects from RT. 76
(75.24%) was performed ALND: 11(21%) with macrometastases, 2 (8%) micrometastases. 4 (3%) isolated tumor cells and 63 (68%)
non metastases. Mean follow-up 32 months (range 5–59). 76.3% Grades 2–3. Her2 negative 63.3%. Invasive ductal carcinoma and
hormone receptor positive majority. Received hormone therapy 92% and chemotherapy 73.6%. 2 patients developed metastases,
4 deaths, 1 per progression.
Conclusion. In our series, the rate of additional axillary disease in patients with micrometastases in SLNB is low. However 14% have
disease>2mm. A selected subgroup of patients N1mi, could be avoided ALND without deteriorating its forecast. The decision of
ALND should be individualized considering multiple factors. We did not ﬁnd association between additional disease and size,
grade, Ki67/Her2 status or histological type.
http://dx.doi.org/10.1016/j.rpor.2013.03.719
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Objective. Evaluate toxicity, aesthetic result and outcome in the ﬁrst 294 breast cancer patients (pts) treated with hypofractionated
radiotherapy (HFRT) scheme at 2 years of follow up.
Material and methods. Clinical records of 294 breast cancer pts receiving postoperative HPRT after conservative surgery pts had
been evaluated. Age: mean 57.26 years (range 30–80). Tumor location: 54.08% (158) of the pts on the right breast and 45.92%
(136) on the left. Surgical treatment: lumpectomy+sentinel lymph node technique (181 pts, 61.56%), quandrantectomy+axillary
dissection (60 pts, 20.40%), and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI (94.89%). Tumor size: 1.39 cm
(range 0.4–5.8). Histological grade: GI 29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) with positive margins.
Hormone receptors: (−) in 6.46%. HER-2: (−) in 11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: mean 12.5 (range
1–24). Positive 1.02 (range 0–2). Stage: I 70.06%, II 27.55%, and III 2.39%. HFRT schedule: Breast: 40.5Gy in 15 fractions of 2.7Gy.
Boost: 103 pts (35.03%) received no boost, 191 (64.97%) received 13.5Gy/5 fr. Adjuvant chemotherapy: 52.38%. Hormone therapy:
58.87%. Follow-up schedule: weekly based during HPRT, 1 month after its completion and, later, every three months.
Results. 77 pts (26.19%) developed radiodermitis. 64 Grade I and 13 Grade II. Mean dose of radiodermitis appearance: 34.92Gy
(range 13.5–46.5). At 6 months, 17 pts (5.78%) had a slight residual hyperpigmentation in the treated area. At 1 year only 5 pts
(1.70%) presented it. At 2 years 2 local relapse have occurred and all remaining pts had a normal-looking skin.
Conclusions. Toxicity and local control of HFRT are equivalent to that obtained with conventional fractionation. Besides, HFRT
reduces total time of treatment and a decrease in the waiting list is achieved.
http://dx.doi.org/10.1016/j.rpor.2013.03.720
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Introduction. If we review literature, radiation-related complication rates seem to be higher among women undergoing
expander/implant reconstruction, irrespective of when RT is given in relation to surgery. The late results of the complex tissue
changes induced by RT are capsular contracture, impaired skin healing, implant rupture, malpositioning or extrusion. However,
not all studies indicate poor cosmetic/aesthetic outcomes or satisfaction in women who undergo immediate reconstruction
followed by RT. In general, if there is indication of administering adjuvant radiotherapy, delayed reconstruction is preferred. But
in some cases this is impossible, either because the indication for postoperative radiation therapy arises after surgery, either by
explicit request of the patient.
Objective. To show our experience in treating patients after breast reconstruction with a breast expander.
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Materials and methods. We evaluated all the patients treated in our department after breast reconstruction with expanders. All of
them started the treatment after the last expansion and all were treated with full expander. Aesthetic evaluation was performed
by the Aesthetic and Plastic Surgery Department. If necessary, patients received local massages for early intervention on ﬁbrosis.
All of them received 50Gy/25 fractions. We studied dosimetric disturbances produced by the expander membrane.
Results. We evaluated 33 patients. We did not observe any difference in acute toxicity compared to conventional treatment or
dosimetric disturbances >5%. None of the patients suffered from infection, dehiscence or necrosis, but all of them experienced
a different grade of ﬁbrosis. This was minimized with the prescription of local massages performed by the Aesthetic and Plastic
Surgery Department. Aesthetic outcome was ﬁnally good or excellent in 90% evaluated by physician and patient.
Conclusion. If we have to treat a reconstructed patient, there is no reason why we should avoid performing it with a full expander,
but all the management should be monitored in a multidisciplinary team.
http://dx.doi.org/10.1016/j.rpor.2013.03.721
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Introduction. Hypofractionated radiation consists on fewer, larger-dose radiation treatments administered in shorter periods than
the standard treatment does. Randomized trials of hypofractionated whole breast irradiation have demonstrated compara-
ble outcomes as conventional fractionation. Doses to organs at risk should be minimized while coverage of the breast is not
compromised.
Purpose. To determine the impact of the different schedules of hypofractionated radiation therapy in breast cancer over organs at
risk and to compare the results with GICOR’s recommendations (Spanish Group of Clinical Investigation in Radiation Oncology)
Methods. Retrospective analyses of dose–volume histogram parameters in organs at risk (lungs, heart, spine and contralateral
breast) in 100 patients treated with hypofractionated external radiation therapy from September 2011 to December 2012 after
breast-conserving surgery. Five groups were formed: (a) breast irradiation without boost, (b) breast irradiation with a boost of
8.01Gy, (c) breast irradiation with a boost of 10.68Gy, (d) breast irradiation with a boost of 13.35Gy and (e) breast irradiation with
supraclavicular area with or without boost. The dose to the whole breast was 40.05Gy.
Results. Median age: 58.7 years. Tumor stage: unknown (Tx or Nx) 3%, 0 (CDIS) 2%, I 65%, II 28%, III 2%. Patient distribution among
groups: group A 26 patients, group B 18 patients, group C 3 patients, group D 49 patients and group E 4 patients. Median breast
volume: 654.7 cm3 (range 260.8–1553.8 cm3). Breast coverage by the prescription dose: 97.5% (range 84.9–100%). Organs at risk:
median ipsilateral lung V30: 101.7 cm3 (range 7.7–253.4 cm3), V20<=25% for both lungs was fulﬁlled in all cases. Median heart
V30 was 2.3 cm3 (range 0–38.1 cm3).
Conclusion. Our series matches GICOR’s recommendations. We recommend the routinely evaluation with dose volume histogram
for all the organs at risk mentioned above in hypofractionated breast irradiation after breast-conserving surgery.
http://dx.doi.org/10.1016/j.rpor.2013.03.722
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Purpose. To evaluate for the ﬁrst time the role of radical radiotherapy at high doses given by hyperfractionated schemes as unique
locoregional treatment as an encouraging alternative to prevent mastectomies in such unresponsive to systemic therapy Stage
IIIB patients.
Patients and methods. 184 women were referred from 1991 to 2010 to hyperfractionated radiotherapy. Mean age 59 years. All but
2 patients (T3) were staged as T4 (84 cases (T4d)) and 88 (47.8%) were classiﬁed as N0. Whole breast was treated to a dose of
60Gy on 1.2Gy/bid, followed by a boost with escalating prescribed doses from 9.6Gy (12 cases), 12Gy (18 cases) and 21.6Gy (154
cases) achieving a total dose of 69.6, 72 and 81.6Gy respectively. Peripheral node areas were treated by conventional fractionation.
Tumor volume mean dose was 79.4±4.7 median 81.6 range 57.6–86.4. Treatment was delivered in 51±8 days, median 50.
Results. Mean follow-up for survivors was 109.44±70.04 months, median 106, range 6–248 months among surviving patients.
Local disease free survival at 5, 10, 15 years was 85.2%, 81.5%, and 81.5%. Cause speciﬁc survival at 5, 10 and 15 years was 60.2%,
50.2% and 37.1%, respectively with a median survival 85±18.96 months (CI 95% 47.83–122.16 months). Radiation dose was the
only prognostic factor for local control (p<0.0001). Toxicity was evaluated by the RTOG scale. Severe acute toxicity (RTOG Grades
3) was present in 32 (17.3%) cases. Severe late cutaneous and subcutaneous toxicity was present in 18% and 30% of the cases,
respectively. DSB analysis and microarrays studies were evaluated in some patients.
